Amarin (AMRN) Vascepa Prescriptions Still Showing Strong Growth (GSK)
Tweet
Share
E-mail
Get Alerts AMRN Hot Sheet
Price: $0.86 -2.27%
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Rating Summary:
6 Buy, 12 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 12 | New: 13
Join SI Premium – FREE
Amarin (Nasdaq: AMRN) is ticking higher early following new Vascepa data from Symphony Health, compiled by Bloomberg Industries (BI).
For its 22nd week on the market, Vascepa prescriptions rose 16 percent to 3,879.0 for the week ended June 7th. That compares with 3,336.0 prescriptions the prior week.
Vascepa competitor, GlaxoSmithKline's (NYSE: GSK) Lovaza, saw just a 12 percent gain in prescriptions to 97,945.0.
No channel blocking or change in projection methodology has been applied to Vascepa since launch, BI said.
Ahead of the bell, Amarin is up 2.4 percent.
For its 22nd week on the market, Vascepa prescriptions rose 16 percent to 3,879.0 for the week ended June 7th. That compares with 3,336.0 prescriptions the prior week.
Vascepa competitor, GlaxoSmithKline's (NYSE: GSK) Lovaza, saw just a 12 percent gain in prescriptions to 97,945.0.
No channel blocking or change in projection methodology has been applied to Vascepa since launch, BI said.
Ahead of the bell, Amarin is up 2.4 percent.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- META to capture largest share of users, SNAP to benefit from ad budget shifts - Canaccord Genuity weighs in on TikTok ban
- Weatherford International plc (WFRD) PT Raised to $184 at Piper Sandler
- Keefe, Bruyette & Woods Upgrades Trustmark (TRMK) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
